Effect of thrombin peptide 508 (TP508) on bone healing during distraction osteogenesis in rabbit tibia

• Published in: Cell and tissue research Vol. 330; no. 1; pp. 35 - 44
• Main Authors: Amir, Lisa R, Li, Gang, Schoenmaker, Ton, Everts, Vincent, Bronckers, Antonius L J J
• Format: Journal Article
• Language: English
• Published: Germany Springer Nature B.V 01.10.2007; Springer-Verlag
• Subjects: Animals; Animals, Newborn; Antibodies, Monoclonal; Bones; Cell Line; Cellular biology; Core Binding Factor Alpha 1 Subunit - physiology; Disease Models, Animal; Histology; Immune system; Male; Mice; Osteoblasts - cytology; Osteoblasts - drug effects; Osteoblasts - physiology; Osteogenesis - drug effects; Osteogenesis - physiology; Osteopontin - physiology; Peptide Fragments - pharmacology; Peptides; Rabbits; Regeneration - drug effects; Regeneration - physiology; Regular; Thrombin - pharmacology; Tibia - injuries; Wound Healing - drug effects; Wound Healing - physiology
• ISSN: 0302-766X; 1432-0878
• DOI: 10.1007/s00441-007-0448-9

Thrombin-related peptide 508 (TP508) accelerates bone regeneration during distraction osteogenesis (DO). We have examined the effect of TP508 on bone regeneration during DO by immunolocalization of Runx2 protein, a marker of osteoblast differentiation, and of osteopontin (OPN) and bone sialoprotein (BSP), two late markers of the osteoblast lineage. Distraction was performed in tibiae of rabbits over a period of 6 days. TP508 (30 or 300 microg) or vehicle was injected into the distraction gap at the beginning and end of the distraction period. Two weeks after active distraction, tissue samples were harvested and processed for immunohistochemical analysis. We also tested the in vitro effect of TP508 on Runx2 mRNA expression in osteoblast-like (MC3T3-E1) cells by polymerase chain reaction analysis. Runx2 and OPN protein were observed in preosteoblasts, osteoblasts, osteocytes of newly formed bone, blood vessel cells and many fibroblast-like cells of the soft connective tissue. Immunostaining for BSP was more restricted to osteoblasts and osteocytes. Significantly more Runx2- and OPN-expressing cells were seen in the group treated with 300 microg TP508 than in the control group injected with saline or with 30 microg TP508. However, TP508 failed to increase Runx2 mRNA levels significantly in MC3T3-E1 cells after 2-3 days of exposure. Our data suggest that TP508 enhances bone regeneration during DO by increasing the proportion of cells of the osteoblastic lineage. Clinically, TP508 may shorten the healing time during DO; this might be of benefit when bone regeneration is slow.